Physician profile
Pradeep Mathur
NPI 1053373159
$9,646.00
in general payments reported to CMS, 2019-2025
35 companies · $2,472 in 2025
The $2,472 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $200 · 2021: $574 · 2022: $1,538 · 2023: $1,820 · 2024: $1,890 · 2025: $2,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,128 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,128.11 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.31 | 2021-2025 | |
| Corium, LLC | $918.01 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $774.56 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $717.98 | 2022-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $686.23 | 2019-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $561.00 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $484.87 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $435.07 | 2019-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $410.18 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $353.90 | 2021-2025 | Caplyta |
| Lundbeck LLC | $315.28 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $287.01 | 2023-2025 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $270.86 | 2021-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $242.25 | 2022-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $230.45 | 2019-2023 | Dyanavel Xr |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $221.41 | 2022-2025 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $215.11 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $182.47 | 2019 | |
| Neos Therapeutics, Lp | $161.68 | 2019-2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $137.44 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $132.31 | 2025 | Jornay Pm |
| Shire North American Group INC | $114.84 | 2019 | |
| Vertical Pharmaceuticals, LLC | $109.25 | 2019-2024 | Relexxii |
| Almatica Pharma LLC | $101.09 | 2024-2025 | Loreev Xr |
| Allergan, INC. | $67.60 | 2019-2020 | |
| Neuronetics, INC. | $47.96 | 2022 | |
| Tempus Ai, INC | $37.77 | 2024 | |
| Avion Pharmaceuticals | $30.17 | 2023 | Methylphenidate Hydrochloride |
| Inspire Medical Systems, INC. | $25.36 | 2025 | Inspire |
| Owp Pharmaceuticals, INC. | $21.11 | 2024 | Subvenite |
| Eisai INC. | $18.23 | 2021 | |
| Aytu Biopharma, INC. | $17.68 | 2021 | |
| Adlon Therapeutics L.P. | $13.00 | 2019 | |
| Alfasigma USA, INC. | $11.12 | 2020 | |
| Validus Pharmaceuticals LLC | $3.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.